ArticleCritical care medicine2015
Xenon improves neurologic outcome and reduces secondary injury following trauma in an in vivo model of traumatic brain injury.
Article in Critical care medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Neuroprotection by the noble gases argon and xenon as treatments for acquired brain injury: a preclinical systematic review and meta-analysis.British journal of anaesthesia · 2022Pooled it
- Medical Gas Therapy for Tissue, Organ, and CNS Protection: A Systematic Review of Effects, Mechanisms, and Challenges.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Pooled it
- Inhalational Gases for Neuroprotection in Traumatic Brain Injury.Journal of neurotrauma · 2021Pooled it
- Xenon Encapsulation in Liposomes, Nanobubbles, and Microbubbles: Delivery Strategies, Preclinical Evidence, and Translational Barriers.Pharmaceutics · 2026Review
- Noble gases xenon and argon: from cellular signalling mechanisms to organoprotection and clinical applications.Journal of translational medicine · 2026Review
- Neuroprotective effects of noble gases following acquired brain injury: a narrative review.Frontiers in pharmacology · 2026Review
- Review
- Repetitive, but Not Single, Mild Blast TBI Causes Persistent Neurological Impairments and Selective Cortical Neuronal Loss in Rats.Brain sciences · 2023Article
- Article
- Therapeutic management of severe spinal cord decompression sickness in a hyperbaric center.Frontiers in medicine · 2023Article
- Neuro-Inflammation Modulation and Post-Traumatic Brain Injury Lesions: From Bench to Bed-Side.International journal of molecular sciences · 2022Review
- Xenon attenuated neonatal lipopolysaccharide exposure induced neuronal necroptosis and subsequently improved cognition in juvenile rats.Frontiers in pharmacology · 2022Article
- Research Progress on the Inflammatory Effects of Long Non-coding RNA in Traumatic Brain Injury.Frontiers in molecular neuroscience · 2022Review
- Noble Gases Therapy in Cardiocerebrovascular Diseases: The Novel Stars?Frontiers in cardiovascular medicine · 2022Review
- Noble gas and neuroprotection: From bench to bedside.Frontiers in pharmacology · 2022Review
- Can Ultrasound-Guided Xenon Delivery Provide Neuroprotection in Traumatic Brain Injury?Neurotrauma reports · 2022Article
- Fecal Microbiota Transplantation Is a Promising Method to Restore Gut Microbiota Dysbiosis and Relieve Neurological Deficits after Traumatic Brain Injury.Oxidative medicine and cellular longevity · 2021Article
- Perinatal hypoxic-ischemic damage: review of the current treatment possibilities.Physiological research · 2020Review
- Xenon treatment after severe traumatic brain injury improves locomotor outcome, reduces acute neuronal loss and enhances early beneficial neuroinflammation: a randomized, blinded, controlled animal study.Critical care (London, England) · 2020Article
- Update of the organoprotective properties of xenon and argon: from bench to beside.Intensive care medicine experimental · 2020Review
Corrections and comments
- Commented on by
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
objectivesTo determine the neuroprotective efficacy of the inert gas xenon following traumatic brain injury and to determine whether application of xenon has a clinically relevant therapeutic time window.
designControlled animal study.
settingUniversity research laboratory. SUBJECTS: Male C57BL/6N mice (n = 196).
interventionsSeventy-five percent xenon, 50% xenon, or 30% xenon, with 25% oxygen (balance nitrogen) treatment following mechanical brain lesion by controlled cortical impact. MEASUREMENTS AND MAIN
resultsOutcome following trauma was measured using 1) functional neurologic outcome score, 2) histological measurement of contusion volume, and 3) analysis of locomotor function and gait. Our study shows that xenon treatment improves outcome following traumatic brain injury. Neurologic outcome scores were significantly (p < 0.05) better in xenon-treated groups in the early phase (24 hr) and up to 4 days after injury. Contusion volume was significantly (p < 0.05) reduced in the xenon-treated groups. Xenon treatment significantly (p < 0.05) reduced contusion volume when xenon was given 15 minutes after injury or when treatment was delayed 1 or 3 hours after injury. Neurologic outcome was significantly (p < 0.05) improved when xenon treatment was given 15 minutes or 1 hour after injury. Improvements in locomotor function (p < 0.05) were observed in the xenon-treated group, 1 month after trauma.
conclusionsThese results show for the first time that xenon improves neurologic outcome and reduces contusion volume following traumatic brain injury in mice. In this model, xenon application has a therapeutic time window of up to at least 3 hours. These findings support the idea that xenon may be of benefit as a neuroprotective treatment in patients with brain trauma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.